Equities research analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to report earnings of ($1.07) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Blueprint Medicines’ earnings, with the highest EPS estimate coming in at ($1.01) and the lowest estimate coming in at ($1.17). Blueprint Medicines posted earnings of ($0.75) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 42.7%. The firm is expected to issue its next quarterly earnings results before the market opens on Wednesday, February 21st.

According to Zacks, analysts expect that Blueprint Medicines will report full year earnings of ($3.75) per share for the current fiscal year, with EPS estimates ranging from ($3.86) to ($3.69). For the next year, analysts forecast that the company will post earnings of ($4.28) per share, with EPS estimates ranging from ($4.87) to ($3.69). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Blueprint Medicines.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have weighed in on the company. Raymond James Financial set a $82.00 price objective on Blueprint Medicines and gave the company a “buy” rating in a report on Sunday, December 10th. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Friday, November 10th. Canaccord Genuity reiterated a “buy” rating and issued a $80.00 target price (up previously from $66.00) on shares of Blueprint Medicines in a research note on Wednesday, November 1st. Morgan Stanley lifted their target price on shares of Blueprint Medicines from $45.00 to $78.00 and gave the company an “overweight” rating in a research note on Monday, October 23rd. Finally, BidaskClub cut shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company’s stock. Blueprint Medicines presently has a consensus rating of “Buy” and a consensus price target of $84.20.

In other news, insider Marion Dorsch sold 18,334 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the completion of the transaction, the insider now owns 18,334 shares in the company, valued at $1,199,960.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 12,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $80.42, for a total transaction of $1,005,250.00. Following the completion of the transaction, the director now owns 174,342 shares of the company’s stock, valued at approximately $14,020,583.64. The disclosure for this sale can be found here. Insiders sold 55,109 shares of company stock valued at $4,022,561 in the last quarter. 3.40% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares during the last quarter. Rockefeller Financial Services Inc. bought a new position in Blueprint Medicines in the 3rd quarter worth approximately $160,000. Ameritas Investment Partners Inc. raised its position in Blueprint Medicines by 68.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares during the last quarter. QS Investors LLC bought a new position in Blueprint Medicines in the 4th quarter worth approximately $173,000. Finally, First Mercantile Trust Co. bought a new position in Blueprint Medicines in the 4th quarter worth approximately $183,000. Hedge funds and other institutional investors own 83.79% of the company’s stock.

Blueprint Medicines (NASDAQ BPMC) traded down $1.11 during midday trading on Friday, reaching $81.44. The company’s stock had a trading volume of 183,449 shares, compared to its average volume of 299,722. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3,539.97, a P/E ratio of -23.88 and a beta of 1.16. Blueprint Medicines has a 12 month low of $32.43 and a 12 month high of $92.00.

WARNING: “-$1.07 Earnings Per Share Expected for Blueprint Medicines Corp (BPMC) This Quarter” was first published by Marea Informative and is the property of of Marea Informative. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.mareainformativa.com/2018/02/17/1-07-earnings-per-share-expected-for-blueprint-medicines-corp-bpmc-this-quarter.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.